Back to Archived Journals » Vaccine: Development and Therapy » Volume 6

Tularemia vaccine development: paralysis or progress?

Authors Sunagar R, Kumar S, Franz B, Gosselin E

Received 4 December 2015

Accepted for publication 8 March 2016

Published 4 May 2016 Volume 2016:6 Pages 9—23

DOI https://doi.org/10.2147/VDT.S85545

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Senthilkumar Palaniyandi

Peer reviewer comments 3

Editor who approved publication: Professor Don Diamond


Raju Sunagar, Sudeep Kumar, Brian J Franz, Edmund J Gosselin

Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY, USA

Abstract: Francisella tularensis (Ft) is a gram-negative intercellular pathogen and category A biothreat agent. However, despite 15 years of strong government investment and intense research focused on the development of a US Food and Drug Administration-approved vaccine against Ft, the primary goal remains elusive. This article reviews research efforts focused on developing an Ft vaccine, as well as a number of important factors, some only recently recognized as such, which can significantly impact the development and evaluation of Ft vaccine efficacy. Finally, an assessment is provided as to whether a US Food and Drug Administration-approved Ft vaccine is likely to be forthcoming and the potential means by which this might be achieved.

Keywords: Sex bias, media impact, differential protection, cellular immunity, humoral immunity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]